Abstract 1423P
Background
Lymphangitic carcinomatosis (LC) is a pathological feature secondary to lymphatic or haematological spread, without an immune cell infiltrate but with radiological appearances of inflammation. Immunotherapy (IO) is now standard of care in early and late-stage non-small cell lung cancer (NSCLC). LC correlates with poor prognosis, but its effects on immunotherapy response are unknown. Here we aim to explore the predictive relevance of the radiological diagnosis of LC in patients with advanced NSCLC treated with single agent immunotherapy (SAIO) or with chemo-immunotherapy (CIO).
Methods
Demographic and clinical data of patients treated with first-line IO between January 2016 and December 2020 was retrospectively collected, and patients with LC identified using pre-treatment CT reports. A paired control arm matched for gender, age (≤70 or >70), smoking status, PS, PDL1 (<1%, 1-49% and ≥50%), stage and treatment was used to compare clinical outcomes. Chi-square Log-Rank (Mantel-Cox) test was used to compare Progression-Free Survival (PFS) and Overall Survival (OS).
Results
A total of 484 patients had been treated with first-line SAIO or CIO, 46 (10.6%) with LC. 41 of them (89%) had non-squamous histology. 29 (63%) were treated with SIAO and 17 (37%) with CIO. Comparing tumours with LC versus the rest, PDL1 expression was <1%; 24 vs 11%, 1-49%; 9 vs 11% and ≥50%; 65 vs 71%. Grade 3/4 IO toxicity rates were similar (48% vs 45%). Comparing patients with LC versus a paired control population (n=73), overall response rates were 28% vs 56%, with disease progression rates of 37 vs 25%. Median PFS was 5 vs 9 months (HR 1.57, 95% C.I. 1.054 – 2.35, p=0.019) and median OS was 9 vs 17 months (HR 1.49, 95% C.I. 0.995 – 2.224, p=0.046). Brain metastases on progression were more common in patients with LC (20% vs 8%). Using univariate Cox regression analysis, PFS and OS were not influenced by the treatment received (SAIO or CIO).
Conclusions
Lymphangitis Carcinomatosis (LC) in patients with NSCLC treated with immunotherapy correlated with lower response rates, poorer PFS and OS. Addition of chemotherapy did not improve outcomes. LC may represent a pre-treatment marker of primary resistance to immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Clatterbridge Cancer Centre.
Funding
Has not received any funding.
Disclosure
C. Escriu: Financial Interests, Personal, Advisory Board: MSD, Roche; Financial Interests, Personal, Invited Speaker: MSD, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
1401P - Impact of KRAS mutation on non-small cell lung cancer survival outcomes
Presenter: Quentin Thomas
Session: Poster session 20
1402P - Real-world routine KRAS testing practices in France for patients (pts) with advanced or metastatic (AM) non-small cell lung cancer (NSCLC): Data from the ESME cohort
Presenter: Clarisse Audigier Valette
Session: Poster session 20
1403P - Sotorasib in KRAS p.G12C mutated advanced NSCLC: Real-word data from the Italian Expanded Access Program
Presenter: Maria Lucia Reale
Session: Poster session 20
1404P - Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU)
Presenter: Herve Lena
Session: Poster session 20
1405P - Sotorasib in KRAS G12C-mutated NSCLC: A multicenter real-world experience from the expanded access program in Germany
Presenter: Friederike Althoff
Session: Poster session 20
1406P - Outcomes of patients with metastatic EGFR mutant lung cancer requiring dose modifications of first line osimertinib
Presenter: J. Connor Wells
Session: Poster session 20
1407P - Characteristics and treatment sequences of patients (pts) with KRAS G12C, other KRAS and non-KRAS advanced or metastatic (AM) non-small cell lung cancer (NSCLC) in the French ESME cohort
Presenter: Nicolas Girard
Session: Poster session 20
1408P - Differences on immune biomarkers between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer
Presenter: Laura Masfarre Pinto
Session: Poster session 20
1409P - DEnosumab in combination with PD-1 checkpoint blockade for MAINtenance therapy of KRAS-mutant advanced NSCLC after first-line immunotherapy: A prospective, single-arm, phase II trial (DEMAIN)
Presenter: Hong-Shuai Li
Session: Poster session 20
1410P - Characterization of patients with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation and their associated direct healthcare costs in Spanish routine clinical practice (SILK study)
Presenter: Noemi Reguart Aransay
Session: Poster session 20